In Vivo is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

InSightec Ltd.

Division of Insightec Ltd.
www.insightec.com

Latest From InSightec Ltd.

Medtech Business Models: All Razor And No Blades – Is “Big Iron” Back In Vogue?

The conventional wisdom in the medtech industry is to pursue the “razor-razor blade” business model, as each placement of capital equipment generates a lucrative annuity of recurring revenues from disposables. The corollary to this conventional wisdom is that so-called “big iron” is to be avoided as, in sharp contrast, it suffers from greater early cash requirements and longer sales cycles that create difficulties forecasting quarterly revenues, and provides no annuities. But that view is no longer the only one that counts, Health Advances CEO Mark Speers argues.

Market Intelligence Business Strategies

Market Intel: New Thermal Therapies Blaze Trail In Fast-Growing Cancer Ablation Market

Cancer rates are rising worldwide and as diagnostic techniques continue to improve, new surgical ablation devices are becoming crucial weapons in the growing arsenal of cancer treatment tools. These devices allow doctors to burn away tumors with precision, speed and safety, without the side-effects that patients undergoing radical cancer therapy often experience. This article provides an overview of the cancer ablation market, highlights the key players working on these devices and discusses their potential applications. It also includes critical insights from a leading interventional urologist on the pros and cons of using these various technologies in treating prostate cancer.

Cancer Surgical Procedures

Device/Diagnostics Quarterly Deal-Making Statistics, Q4 2017

Device fundraising during the fourth quarter totaled $2.6 billion, making it the strongest quarter of the year. Q4 M&A activity reached $3.9 billion, higher than Q3's $3.4 billion, but still one of the lowest quarters of the year. Both fourth quarter diagnostics financings and M&As hit an all-year low of $622 million, and $2.8 million, respectively.

Deals Market Intelligence

European Life Sciences Start-Ups Maintain Early Investor Allure

Venture capital investment in life sciences companies continues to rise. In 2017, biopharma and medtech start-ups raised $19.7 billion worldwide. European businesses retained a robust share of that global take and investors expect that trend to continue.

Europe Financing
See All

Company Information

  • Industry
  • Medical Devices
    • Diagnostic Imaging Equipment & Supplies
      • MRI, NMR
      • Ultrasound
    • Surgical Equipment & Devices
      • Minimally or Less Invasive
  • Therapeutic Areas
  • Cancer
  • Gynecological, Urological
  • Musculoskeletal & Connective Tissue Disorders
  • Neurology, Nervous System
  • Alias(es)
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • Middle East
      • Israel
  • Parent & Subsidiaries
  • Insightec Ltd.
  • Senior Management
  • Maurice R Ferre, MD, CEO & Chmn.
    Roni Karie, VP, CFO
    Moni Carmeli, VP, R&D
    Xen Mendelsohn Aderka, VP, Mktg.
    Jun Tao, Chief Commercial Officer
    Nadir Alikacem, PhD, VP, Global Reg. Affairs & CRO
    Baruch Avruch, VP, Operations & Quality
    Yoav Levy, PhD, CSO
  • Contact Info
  • InSightec Ltd.
    Phone: (972) 4 8131313
    5 Nahum Heth St.
    P.O. Box 2059 Tirat Carmel, 39120
    Israel
Advertisement
Advertisement
UsernamePublicRestriction

Register